-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since October, news about the listing of pharmaceutical companies has continued
.
Following Huiyu Pharmaceutical’s listing on the Sci-tech Innovation Board, on October 27, 2021, Tuoxin Pharmaceutical officially listed on the Growth Enterprise Market.
The opening price on the first day of listing was RMB 26.
51 per share.
The number of shares issued this time was 31.
5 million shares.
The total share capital after the public offering is 126 million shares
.
According to the data, Tuoxin Pharmaceutical is an enterprise integrating chemical synthesis, bio-fermentation nucleoside (acid) APIs and pharmaceutical intermediates R&D, production and sales.
The company has domestic nucleoside (acid) APIs and The R&D field of pharmaceutical intermediates started early, with large scale and complete varieties, and has formed a relatively complete product chain from basic products to high-end products
.
At present, the company has multiple series of nucleoside (acid) products such as pyrimidine series, purine series, nucleotide series and nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, Cytosine, 5-fluorocytosine, cytidine and other raw materials and pharmaceutical intermediates mainly cover the fields of antiviral, antitumor and nervous system drugs
.
It is understood that Tuoxin Pharmaceuticals sprinted for the GEM IPO this year, and successfully passed the meeting in early April, and finally successfully listed after more than 6 months
.
According to the prospectus issued by Tuoxin Pharmaceuticals, in terms of listing standards, Tuoxin Pharmaceuticals chose the listing standard of "the net profit in the last two years has been positive, and the cumulative net profit is not less than 50 million yuan"
.
In terms of financial data, the company has achieved strong profitability in recent years
.
From 2018 to 2020, Tuoxin Pharmaceuticals achieved operating income of 391 million yuan, 386 million yuan, and 528 million yuan, respectively; the net profit attributable to the owners of the parent company during the same period was 63,219,100 yuan, 61,251,800 yuan, and 113 million yuan.
Yuan; the company's main business gross profit margins were 45.
34%, 41.
06% and 43.
37% in the same period, which was generally at a relatively high level
.
In addition, in terms of R&D investment, Tuoxin Pharmaceuticals attaches great importance to the investment in product R&D and the improvement of its own R&D comprehensive strength
.
In the past three years, the company invested 13.
448900 yuan in R&D in 2018; 15.
5241 million yuan in R&D in 2019; 18.
824 million yuan in R&D in 2020
.
On the whole, R&D expenses have shown an increasing trend year by year
.
Tuoxin Pharmaceutical intends to raise 602 million yuan this time, and the funds raised will be invested in the construction of nucleoside series of specialty APIs and pharmaceutical intermediates, the construction project of Tuoxin Pharmaceutical Research Institute and supplementary working capital
.
Among them, the total investment in the construction project of nucleoside series of specialty APIs and pharmaceutical intermediates is 300 million yuan, and the project intends to use raised funds of 235 million yuan; the total investment in the construction project of Tuoxin Pharmaceutical Research Institute is 60 million yuan, all of which will be raised; the other 100 million yuan Yuan raised funds are used to supplement working capital
.
A total of 395 million yuan of raised funds have been used
.
At present, Tuoxin Pharmaceutical has formed two core technologies for the production of nucleosides by chemical synthesis and biological fermentation, and has a number of core products and products under development with high market competitiveness, which are the company's continuous, rapid, and An important foundation has been laid for healthy development
.
It is reported that in the future, Tuoxin Pharmaceutical will take the global pharmaceutical industry reform as an opportunity, pay close attention to the development trend of the API industry, continue to focus on the company’s main business, focus on the nucleoside (acid) field, adhere to the path of specialization, and actively introduce various Class high-level technical talents and excellent management talents, improve the technology research and development system, increase cooperation between industry, university and research, and enhance the company's research and development level and independent innovation capabilities
.
.
Following Huiyu Pharmaceutical’s listing on the Sci-tech Innovation Board, on October 27, 2021, Tuoxin Pharmaceutical officially listed on the Growth Enterprise Market.
The opening price on the first day of listing was RMB 26.
51 per share.
The number of shares issued this time was 31.
5 million shares.
The total share capital after the public offering is 126 million shares
.
According to the data, Tuoxin Pharmaceutical is an enterprise integrating chemical synthesis, bio-fermentation nucleoside (acid) APIs and pharmaceutical intermediates R&D, production and sales.
The company has domestic nucleoside (acid) APIs and The R&D field of pharmaceutical intermediates started early, with large scale and complete varieties, and has formed a relatively complete product chain from basic products to high-end products
.
At present, the company has multiple series of nucleoside (acid) products such as pyrimidine series, purine series, nucleotide series and nucleoside series, including citicoline sodium, ribavirin, inosine, acyclovir, Cytosine, 5-fluorocytosine, cytidine and other raw materials and pharmaceutical intermediates mainly cover the fields of antiviral, antitumor and nervous system drugs
.
It is understood that Tuoxin Pharmaceuticals sprinted for the GEM IPO this year, and successfully passed the meeting in early April, and finally successfully listed after more than 6 months
.
According to the prospectus issued by Tuoxin Pharmaceuticals, in terms of listing standards, Tuoxin Pharmaceuticals chose the listing standard of "the net profit in the last two years has been positive, and the cumulative net profit is not less than 50 million yuan"
.
In terms of financial data, the company has achieved strong profitability in recent years
.
From 2018 to 2020, Tuoxin Pharmaceuticals achieved operating income of 391 million yuan, 386 million yuan, and 528 million yuan, respectively; the net profit attributable to the owners of the parent company during the same period was 63,219,100 yuan, 61,251,800 yuan, and 113 million yuan.
Yuan; the company's main business gross profit margins were 45.
34%, 41.
06% and 43.
37% in the same period, which was generally at a relatively high level
.
In addition, in terms of R&D investment, Tuoxin Pharmaceuticals attaches great importance to the investment in product R&D and the improvement of its own R&D comprehensive strength
.
In the past three years, the company invested 13.
448900 yuan in R&D in 2018; 15.
5241 million yuan in R&D in 2019; 18.
824 million yuan in R&D in 2020
.
On the whole, R&D expenses have shown an increasing trend year by year
.
Tuoxin Pharmaceutical intends to raise 602 million yuan this time, and the funds raised will be invested in the construction of nucleoside series of specialty APIs and pharmaceutical intermediates, the construction project of Tuoxin Pharmaceutical Research Institute and supplementary working capital
.
Among them, the total investment in the construction project of nucleoside series of specialty APIs and pharmaceutical intermediates is 300 million yuan, and the project intends to use raised funds of 235 million yuan; the total investment in the construction project of Tuoxin Pharmaceutical Research Institute is 60 million yuan, all of which will be raised; the other 100 million yuan Yuan raised funds are used to supplement working capital
.
A total of 395 million yuan of raised funds have been used
.
At present, Tuoxin Pharmaceutical has formed two core technologies for the production of nucleosides by chemical synthesis and biological fermentation, and has a number of core products and products under development with high market competitiveness, which are the company's continuous, rapid, and An important foundation has been laid for healthy development
.
It is reported that in the future, Tuoxin Pharmaceutical will take the global pharmaceutical industry reform as an opportunity, pay close attention to the development trend of the API industry, continue to focus on the company’s main business, focus on the nucleoside (acid) field, adhere to the path of specialization, and actively introduce various Class high-level technical talents and excellent management talents, improve the technology research and development system, increase cooperation between industry, university and research, and enhance the company's research and development level and independent innovation capabilities
.
